Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

53 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Translating clinical trials to clinical practice: outcomes of men with metastatic castration resistant prostate cancer treated with docetaxel and prednisone in and out of clinical trials.
Templeton AJ, Vera-Badillo FE, Wang L, Attalla M, De Gouveia P, Leibowitz-Amit R, Knox JJ, Moore M, Sridhar SS, Joshua AM, Pond GR, Amir E, Tannock IF. Templeton AJ, et al. Ann Oncol. 2013 Dec;24(12):2972-7. doi: 10.1093/annonc/mdt397. Epub 2013 Oct 14. Ann Oncol. 2013. PMID: 24126362 Free article.
Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer.
Leibowitz-Amit R, Templeton AJ, Omlin A, Pezaro C, Atenafu EG, Keizman D, Vera-Badillo F, Seah JA, Attard G, Knox JJ, Sridhar SS, Tannock IF, de Bono JS, Joshua AM. Leibowitz-Amit R, et al. Ann Oncol. 2014 Mar;25(3):657-662. doi: 10.1093/annonc/mdt581. Epub 2014 Jan 23. Ann Oncol. 2014. PMID: 24458472 Free PMC article.
Abiraterone acetate in metastatic castration-resistant prostate cancer: a retrospective review of the Princess Margaret experience of (I) low dose abiraterone and (II) prior ketoconazole.
Leibowitz-Amit R, Seah JA, Atenafu EG, Templeton AJ, Vera-Badillo FE, Alimohamed N, Knox JJ, Tannock IF, Sridhar SS, Joshua AM. Leibowitz-Amit R, et al. Eur J Cancer. 2014 Sep;50(14):2399-407. doi: 10.1016/j.ejca.2014.06.004. Epub 2014 Jul 16. Eur J Cancer. 2014. PMID: 25042152
Choosing a better end point for trials of bone-protective agents.
Leibowitz-Amit R, Khoja L, Tannock IF, Joshua AM. Leibowitz-Amit R, et al. Ann Oncol. 2015 May;26(5):1032-1033. doi: 10.1093/annonc/mdv039. Epub 2015 Jan 28. Ann Oncol. 2015. PMID: 25632065 Free article. No abstract available.
53 results